In vitro studies have shown that inhibition of cell viability of prostate cancer cells by GT3 is the result of a multipronged effect that involves the activation of the JNK pathway and suppression of NF-κB via downregulation of EGFR and Id-1. This evidence concerns the gene NFKB1 and prostate cancer.